James M Russell

Summary

Affiliation: University of Texas Medical Branch
Country: USA

Publications

  1. ncbi Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline
    J M Russell
    University of Texas Medical Branch, Galveston 77555 0191, USA
    Am J Manag Care 5:597-606. 1999
  2. ncbi Chronic depression and comorbid personality disorders: response to sertraline versus imipramine
    James M Russell
    Department of Psychiatry and Behavioral Sciences, The University of Texas Medical Branch at Galveston, 77555, USA
    J Clin Psychiatry 64:554-61. 2003
  3. ncbi Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression
    David L Dunner
    Center for Anxiety and Depression, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105, USA
    J Clin Psychiatry 67:688-95. 2006
  4. ncbi Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies
    Jonathan Davidson
    Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    Hum Psychopharmacol 23:519-26. 2008
  5. ncbi The cost consequences of treatment-resistant depression
    James M Russell
    University of Texas Medical Branch, Galveston, TX, USA
    J Clin Psychiatry 65:341-7. 2004
  6. ncbi Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
    Neuropsychopharmacology 30:405-16. 2005
  7. ncbi The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication
    Alan J Gelenberg
    University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
    J Clin Psychiatry 65:1114-9. 2004
  8. ncbi Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies
    Jean Endicott
    New York State Psychiatric Institute and Columbia School of Medicine, New York, NY 10032, USA
    J Clin Psychiatry 68:518-24. 2007
  9. ncbi Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes
    David G Armstrong
    Scholl s Center for Lower Extremity Ambulatory Research CLEAR at Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA
    Pain Med 8:410-8. 2007
  10. ncbi Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms
    James M Russell
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Depress Anxiety 25:E1-11. 2008

Detail Information

Publications15

  1. ncbi Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline
    J M Russell
    University of Texas Medical Branch, Galveston 77555 0191, USA
    Am J Manag Care 5:597-606. 1999
    ..To compare depression-related treatment costs and total healthcare costs for patients diagnosed with depression and treated with either sertraline, paroxetine, or fluoxetine...
  2. ncbi Chronic depression and comorbid personality disorders: response to sertraline versus imipramine
    James M Russell
    Department of Psychiatry and Behavioral Sciences, The University of Texas Medical Branch at Galveston, 77555, USA
    J Clin Psychiatry 64:554-61. 2003
    ..Few studies, though, have systematically examined the clinical correlates of Axis II personality disorder comorbidity or its effect on treatment response or time to response...
  3. ncbi Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression
    David L Dunner
    Center for Anxiety and Depression, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105, USA
    J Clin Psychiatry 67:688-95. 2006
    ..We report on the characteristics and outcomes of a large cohort of patients with a level of treatment resistance that is very substantial and who were treated for 2 years with standard care...
  4. ncbi Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies
    Jonathan Davidson
    Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    Hum Psychopharmacol 23:519-26. 2008
    ..To assess the efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder (GAD)...
  5. ncbi The cost consequences of treatment-resistant depression
    James M Russell
    University of Texas Medical Branch, Galveston, TX, USA
    J Clin Psychiatry 65:341-7. 2004
    ..Disease management interventions for treatment-resistant depression that result in sustained remission early in the course of illness are most likely to be cost effective...
  6. ncbi Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
    Neuropsychopharmacology 30:405-16. 2005
    ..Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings...
  7. ncbi The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication
    Alan J Gelenberg
    University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
    J Clin Psychiatry 65:1114-9. 2004
    ..A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo...
  8. ncbi Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies
    Jean Endicott
    New York State Psychiatric Institute and Columbia School of Medicine, New York, NY 10032, USA
    J Clin Psychiatry 68:518-24. 2007
    ..The present work examined the efficacy of duloxetine treatment for improving functional outcomes for patients with GAD in 3 independent clinical studies...
  9. ncbi Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes
    David G Armstrong
    Scholl s Center for Lower Extremity Ambulatory Research CLEAR at Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA
    Pain Med 8:410-8. 2007
    ..To assess the effectiveness of duloxetine, compared with placebo, on patient-reported health outcomes over a 12-week period, in the management of diabetic peripheral neuropathic pain (DPNP)...
  10. ncbi Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms
    James M Russell
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Depress Anxiety 25:E1-11. 2008
    ..These results suggest that in patients with GAD who present with clinically significant pain symptoms, duloxetine is effective in reducing anxiety symptoms, pain severity, and in improving patient functioning...
  11. ncbi A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder
    David G S Perahia
    Lilly Research Centre, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    J Psychiatr Res 42:22-34. 2008
    ..The objective was to compare the serotonin and norepinephrine reuptake inhibitors (SNRIs) duloxetine and venlafaxine using GBR assessment...
  12. ncbi Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, 3811 O Hara St, Pittsburgh, PA 15213, USA
    Arch Gen Psychiatry 59:233-9. 2002
    ..Although various strategies have been proposed to treat antidepressant nonresponders, little controlled research has been published that examines prospectively the use of switching to an alternate antidepressant...
  13. ncbi Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, 4225 Roosevelt Way NE, Ste 306C, Seattle, WA 98105, United States
    J Affect Disord 87:115-9. 2005
    ..This study investigated the rate of hypomania, mania, and hypomanic-like symptoms observed during treatment with duloxetine in patients with major depression...
  14. ncbi The impact of treatment-resistant depression on health care utilization and costs
    William H Crown
    MEDSTAT Group, Cambridge, Mass, USA
    J Clin Psychiatry 63:963-71. 2002
    ..These findings underscore the need for early identification and effective long-term maintenance treatment for treatment-resistant depression...
  15. ncbi Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724-5002, USA
    Biol Psychiatry 54:806-17. 2003
    ..8%). Somnolence was significantly greater among the patients taking active medication (15.4%), compared with placebo (4.6%). CONCLUSIONS: Nefazodone is well-tolerated and is an effective maintenance therapy for chronic forms of MDD...